Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer

Journal of Clinical Oncology

Volumn 11, Issue 1, 1993, Pages 59-65

  Paterson, A H G ^a   Powles, T J ^b   Kanis, J A ^b   McCloskey, E ^b   Hanson, J ^b   Ashley, S ^b  

^a TOM BAKER CANCER CENTRE   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CLODRONIC ACID; PLACEBO;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL FEATURE; DRUG EFFICACY; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; ORAL DRUG ADMINISTRATION; OSTEOLYSIS; PRIORITY JOURNAL; VERTEBRA FRACTURE; VERTEBRA MALFORMATION;

ADMINISTRATION, ORAL; ADULT; AGED; BONE NEOPLASMS; BREAST NEOPLASMS; CALCIUM; CLODRONIC ACID; DOUBLE-BLIND METHOD; FEMALE; FRACTURES, SPONTANEOUS; HUMAN; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T;

EID: 0027531814     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1993.11.1.59     Document Type: Article

References (42)

1. Paterson AHG: Bone metastases in breast cancer, prostate cancer and myeloma. Bone 8:S17-S22, 1987 (suppl 1)
2. Bremmer RA, Jelliffe AM: The management of pathological fracture of the major long bones from metastatic cancer. J Bone Joint Surg 408:652-658, 1958
3. Mundy GR: Bone resorption and turnover in health and disease. Bone 8:S9-S16, 1987(suppl 1)
4. Mundy GR: Identifying mechanisms for increasing bone mass. J Natl Inst Health Res 1:65-68, 1989
5. Early Breast Cancer Trialist's Collaborative Group: Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 339:71-85, 1992
6. Koyama H, Wada T, Nishizawa Y, et al: Cyclophosphamide induced ovarian failure and its therapeutic significance in patients with breast cancer. Cancer 39:1403-1409, 1977
7. Friedlender GE, Tross RB, Doganis AC, et al: Effects of chemotherapeutic agents on bone. 1. Short-term methotrexate and doxorubicin (Adriamycin) treatment in a rat model. J Bone Joint Surg 66A:602-607, 1984 (abstr)
8. Slayton RE, Schinder BJ, Elias E, et al: New approach to the treatment of hypercalcemia. The effect of short-term treatment with mithramycin. Clin Pharmacol Ther 12:833-837, 1971
9. Ljunghall S: Use of clodronate and calcitonin in hypercalcaemia due to malignancy. Recent Results Cancer Res 116:40-45, 1989
10. Kanis JA, McCloskey EV: The use of clodronate in disorders of calcium and skeletal metabolism. Prog Basic Clin Pharmacol 4: 89-136, 1990
11. Morton AR, Howell A: Bisphosphonates and bone metastases. Br J Cancer 58:556-557, 1988 (editorial)
12. Fleisch H: Bisphosphonates: Mechanism of action and clinical application. Bone Miner Res 1:319-357, 1983
13. Fleisch H: Bisphosphonates: A new class of drugs in diseases of bone and calcium metabolism. Recent Results Cancer Res 116: 1-28, 1989
14. Boonecamp PM, van der Wee-Pais LJA, van Wijk-van Lennep MML, et al: Two modes of action of bisphosphonates on osteoclastic resorption of mineralised matrix. J Bone Miner Res 1:27-39, 1986
15. Plasmans CMT, Kuypers W, Slooff TJJH: The effect of ethane1-hydroxy-1, 1-diphosphonic acid (EHDP) on matrix induced ectopic bone formation. Clin Orthop Rel Res 132:233-243, 1978
16. Altman RD, Johnston CC, Khairi MRA, et al: Influence of disodium etidronate on clinical and laboratory manifestations of Paget's disease of bone (osteitis deformans). N Engl J Med 289:1379-1384, 1973
17. Storm T, Thamsborg G, Steiniche T, et al: Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 322:1265-1271, 1990
18. Ryzen E, Martodam R, Troxell M, et al: Intravenous etidronate in the management of malignant hypercalcaemia. Arch Intern Med 145:449-452, 1985
19. McCloskey EV, Yates AJP, Beneton MNC, et al: Comparative effects of intravenous diphosphonates on calcium and skeletal metabolism in man. Bone 8:S35-S41, 1987 (suppl 1)
20. Kanis JA, Urwin GH, Gray RES, et al: Effects of intravenous etidronate on skeletal and calcium metabolism. Am J Med 82:55-70, 1987
21. van Holten-Verzantvoort AT, Bijvoet OLM, Hermans J, et al: Reduced morbidity from skeletal metastases in breast cancer patients during long-term bisphosphonate (APD) treatment. Lancet 2: 983-985, 1987
22. Percival RC, Yates AJP, Gray RES, et al: Mechanisms of malignant hypercalcaemia in carcinoma of the breast. Br Med J 295: 776-779, 1985
23. Siris ES, Hyman GA, Canfield RE: Effects of dichloromethylene diphosphonate in women with breast carcinoma metastatic to the skeleton. Am J Med 74:401-406, 1983
24. Urwin GH, Yates AJP, Gray RES, et al: Treatment of hypercalcaemia of malignancy with intravenous clodronate. Bone 8:S43-S51, 1987 (suppl 1)
25. Elomaa I, Blomqvist C, Porkka L, et al: Clodronate for osteolytic metastases due to breast cancer. Biomed Pharmacother 42: 111-116, 1988
26. Jung A, Chantraine A, Donath A, et al: Use of dichloromethylene diphosphonate in metastatic bone disease. N Engl J Med 308: 1499-1501, 1983
27. 2MDP) on skeletal lesions in multiple myeloma. Metab Bone Dis Rel Res 4:163-168, 1982
28. 2MBP) on bone disease of myeloma patients treated with chemotherapy. Hematol Oncol 8:23-30, 1990
29. Kanis JA: Pathophysiology and Treatment of Paget's Disease of Bone. Durham, NC, Carolina Academic, Press WE250-K26, 1991
30. Hayward JL, Meakin JW, Stewart HJ: Assessment of response and recurrence in breast cancer. Semin Oncol 5:445-449, 1978
31. Breast Cancer Task Force, Treatment Committee, National Cancer Institute: Breast Cancer: Suggested Protocol Guidelines for Combination Chemotherapy Trials and for Combined Modality Trials. Washington, DC, US Department of Health, Education and Welfare, Publication no. (NIH) 77-1192, 1977
32. Endele R: Quantitative Determination of Clodronic Acid in Body Fluids Documentation. Mannheim, Germany, Boehringer, 1989
33. Kanis JA, Cundy T, Heynen G, et al: The pathophysiology of hypercalcaemia. Metab Bone Dis Rel Res 2:151-159, 1980
34. Bonjour J-P, Philippe J, Guelpa G, et al: Bone and renal components in hypercalcaemia of malignancy and responses to a single infusion of clodronate. Bone 9:123-130, 1988
35. McCloskey GV, Spector T, Eyres KS, et al: Definition of vertebral deformity - A new algorithm for use in population studies and clinical trials. Osteoporosis Int (submitted)
36. Spector TD, McCloskey EV, Mootswang I, et al: The epidemiology of vertebral fractures in the general population. The Clingford Study. J Bone Miner Res 6:277-279, 1991 (suppl)
37. Richardson JL, Shelton DR, Krailo M, et al: The effect of compliance with treatment on survival among patients with hematologic malignancies. J Clin Oncol 8:356-364, 1990
38. Paterson AHG, Ernst D, Powles TJ, et al: Treatment of skeletal disease in breast cancer with clodronate. Bone 12:25-30, 1991 (suppl 1)
39. Ernst DS, MacDonald RN, Paterson AHG, et al: A double blind cross-over trial of IV clodronate in metastatic bone pain. J Pain Sympt Management 7:4-11, 1992
40. Adami S, Mian M: Clodronate therapy of metastatic bone disease in patients with prostate cancer. Recent Results Cancer Res 116:67-72, 1989
41. van Holten-Verzantvoort ATM, Cleton FJ, Hermans J, et al: The treatment of bone metastases in patients with advanced breast cancer with pamidronate (APD, an aminobisphosphonate), in Wüster Chr. Ziegler R (eds): Knochenmetastasen: Pathophysiologie und Therapie. Proceedings of a Symposium, Heidelberg, Germany, October 4, 1990. PMI, pp 36-47
42. Leiras Formulary Brochure. Helsinki, Finland, Huktamaki Oy Leiras, 1991